| GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma (NCT05352542) | jianming xu | 2022-05-19 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax (NCT05092373) | M.D. Anderson Cancer Center | 2022-04-29 |
| Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients (NCT05213221) | Zhejiang University | 2022-03-14 |
| Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma (NCT05317819) | Polaris Group | 2022-03-14 |
| Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT Study (NCT05117957) | Bo Hyun Kim | 2022-03-08 |
| Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma (NCT04430452) | Mary Feng, MD | 2022-02-04 |
| 68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer (NCT05176223) | Mayo Clinic | 2022-01-30 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484) | National Cancer Institute (NCI) | 2021-11-22 |
| Safety and Efficacy of Bifidobacterium Therapy in Patients With Advanced Liver Cancer Receiving Immunotherapy (NCT05620004) | Sun Yat-sen University | 2021-11-01 |
| Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells (NCT05628545) | Guangdong GD Kongming Biotech LLC | 2021-11-01 |
| B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma (NCT05070156) | Tongji University | 2021-10-29 |
| IMC001 for Clinical Research on Advanced Digestive System Malignancies (NCT05028933) | Zhejiang University | 2021-09-30 |
| Cryoablation Combined with Tislelizumab Plus Lenvatinib As Second-line or Later Therapy in Advanced Hepatocellular Carcinoma (NCT05057845) | Fudan University | 2021-09-26 |
| A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC (NCT04948697) | BeiGene | 2021-08-20 |
| Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer (NCT04828486) | Mayo Clinic | 2021-08-17 |
| Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma (NCT04973098) | Peking University | 2021-08-05 |
| Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab (NCT05173298) | CHA University | 2021-08-02 |
| Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma. (NCT05097911) | National University Hospital, Singapore | 2021-08-02 |
| Single-arm, Open-label Clinical Study of SZ003 in the Treatment of Advanced Hepatocellular Carcinoma (NCT05845502) | Shantou University Medical College | 2021-07-26 |
| A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC (NCT04331743) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-06-05 |
| Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC (NCT04862949) | CHA University | 2021-05-01 |
| Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer (NCT04442581) | University of Washington | 2021-04-20 |
| Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004) (NCT04740307) | Merck Sharp & Dohme LLC | 2021-03-16 |
| Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma (NCT04756648) | Zhejiang University | 2021-03-10 |
| Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT (NCT04709380) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2021-03-02 |
| ATEZOLIZUMAB - BEVACIZUMAB in the Treatment Hepatocellular Carcinoma Inoperable or (NCT04730388) | University Hospital, Brest | 2021-01-18 |
| Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma (NCT06323382) | Sun Yat-sen University | 2021-01-01 |
| Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma (NCT04183088) | National Taiwan University Hospital | 2020-12-16 |
| Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection (NCT04294498) | National Taiwan University Hospital | 2020-11-02 |
| Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma (NCT04503902) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2020-10-15 |
| Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular Carcinoma (NCT04401813) | Innovent Biologics (Suzhou) Co. Ltd. | 2020-06-16 |
| Camrelizumab Utilization on Patients With Advanced Liver Cancer (NCT04487704) | First Affiliated Hospital Xi'an Jiaotong University | 2020-04-07 |
| YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) (NCT04000737) | Yiviva Inc. | 2020-01-10 |
| Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC (NCT04611165) | National Cancer Center, Korea | 2019-11-15 |
| To Explore the Diversity of Intestinal Flora in Patients With Advanced HCC Combin ed With Anti-PD-1 and Targeted Drug Therapy and the Correlation Between Metabolites and Therapeutic Effect (NCT04101747) | Sun Yat-sen University | 2019-11-01 |
| Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC) (NCT04066660) | Hi-Q Marine Biotech International, Ltd. | 2019-10-01 |
| 4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3 (NCT03980288) | Zhejiang University | 2019-07-23 |
| TACE Combined With PD-1 Knockout Engineered T Cell in Advanced Hepatocellular Carcinoma. (NCT04417764) | Central South University | 2019-06-20 |
| TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC (NCT03905967) | Sun Yat-sen University | 2019-06-16 |
| Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma (NCT03841201) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2019-06-12 |
| Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC) (NCT04052152) | The First Affiliated Hospital with Nanjing Medical University | 2019-06-10 |
| A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With FOLFOX4 in Subjects With Advanced HCC Who Have Never Received Prior Systemic Treatment. (NCT03605706) | Jiangsu HengRui Medicine Co., Ltd. | 2019-05-31 |
| A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma (NCT03993743) | Xijing Hospital | 2019-05-27 |
| Itacitinib in Advanced Hepatocellular Carcinoma (NCT04358185) | Imperial College London | 2018-12-03 |
| Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma (NCT04072679) | Chinese Academy of Medical Sciences | 2018-10-11 |
| Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT (NCT05592197) | Sun Yat-sen University | 2018-10-01 |
| A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma (NCT03586973) | Takeda | 2018-08-06 |
| Phase 1 Study of SF1126 in Combination With Nivolumab in Patients With Advanced Hepatocellular Carcinoma (NCT03059147) | SignalRX Pharmaceuticals, Inc. | 2017-03-27 |
| Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma (NCT02834780) | H3 Biomedicine Inc. | 2016-12-28 |
| Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma (NCT01964235) | Novartis Pharmaceuticals | 2016-12-01 |
| Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC (NCT02795429) | Novartis Pharmaceuticals | 2016-06-15 |
| A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma (NCT02528643) | Astellas Pharma Global Development, Inc. | 2015-11-09 |
| Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma (NCT02638857) | Second Military Medical University | 2015-09-01 |
| Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma (NCT02632006) | Second Military Medical University | 2015-09-01 |
| Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (NCT02227914) | Amgen | 2014-12-01 |
| Transarterial Chemoembolization (TACE) Plus Sorafenib Versus TACE for Advanced Hepatocellular Carcinoma (NCT02150317) | Eastern Hepatobiliary Surgery Hospital | 2014-01-01 |
| Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCC (NCT01897610) | GC Cell Corporation | 2013-12-01 |
| A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma) (NCT01942083) | Korea Otsuka Pharmaceutical Co., Ltd. | 2013-05-29 |
| Targeted Internal Radiation Therapy in Advanced HCC Patients. (NCT02724267) | Eastern Hepatobiliary Surgery Hospital | 2012-11-01 |
| Study of ARQ 197 in Hepatocellular Carcinoma (HCC) (NCT01656265) | Kyowa Kirin Co., Ltd. | 2012-07-01 |
| Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE (NCT01539018) | Egyptian Society of Liver Cancer | 2012-01-01 |
| A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer (NCT01356628) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2011-05-25 |
| Trial of Palliative Chemotherapy With TS-1 and Oxaliplatin for Patients With Advanced Hepatocellular Carcinoma (NCT01429961) | Seoul National University Hospital | 2011-05-01 |
| Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC (NCT01214343) | Ministry of Health, Labour and Welfare, Japan | 2010-10-01 |
| CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer (NCT01033240) | Daiichi Sankyo | 2010-07-09 |
| A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma (NCT01192971) | Jiangsu HengRui Medicine Co., Ltd. | 2010-06-01 |
| Siliphos in Advanced Hepatocellular Carcinoma (NCT01129570) | Abby Siegel | 2010-02-01 |
| Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients (NCT00999882) | AstraZeneca | 2009-10-01 |
| A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer (NCT00872014) | Amgen | 2009-08-01 |
| XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) (NCT00882869) | Aegera Therapeutics | 2009-03-01 |
| A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma (NCT00756782) | Taiho Oncology, Inc. | 2008-10-01 |
| Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC) (NCT00731445) | Zeria Pharmaceutical | 2008-07-01 |
| Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma (NCT00667628) | Taiho Oncology, Inc. | 2008-04-24 |
| Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC) (NCT00517920) | AbbVie (prior sponsor, Abbott) | 2007-09-01 |
| Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma (NCT00752063) | The University of Hong Kong | 2007-09-01 |
| GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma (NCT00495846) | Federico II University | 2007-04-01 |
| Phase I/II Study of Amplitude-Modulated Electromagnetic Fields in the Treatment of Advanced Hepatocellular Carcinoma (NCT00534664) | University of Sao Paulo | 2005-10-01 |
| Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma (NCT00241020) | Novartis Pharmaceuticals | 2002-06-01 |